Eplontersen

Introduction Overview

Generic Name

Eplontersen

Brand Name

Wainua

Dosage Form

Subcutaneous injection (45 mg/0.8 mL)

Drug Class

Miscellaneous metabolic agents

Pharmacokinetics

Absorption:
Eplontersen is administered via subcutaneous injection, allowing for direct absorption into the systemic circulation through the rich vascular network beneath the skin. Peak plasma concentrations are typically reached several hours after administration, facilitating a sustained systemic exposure. The subcutaneous route allows for slow and controlled uptake, which supports the once-monthly dosing regimen. Factors such as injection site, blood flow, and patient-specific physiology may influence absorption rates. Clinical studies have demonstrated consistent bioavailability allowing reliable dosing in adult patients with hereditary transthyretin-mediated amyloidosis (hATTR-PN).

Distribution:
Once absorbed, eplontersen distributes predominantly within the plasma and extracellular fluid. As an antisense oligonucleotide conjugated to a ligand for efficient hepatocyte delivery, it selectively targets the liver, the primary site of transthyretin (TTR) production. The distribution is influenced by molecular size, charge, and ligand conjugation, facilitating receptor-mediated uptake by hepatocytes. The volume of distribution is limited largely to the vascular and interstitial compartments. Plasma protein binding is moderate, avoiding extensive sequestration which could alter pharmacodynamics.

Metabolism:
Eplontersen undergoes metabolism primarily through endonuclease- and exonuclease-mediated cleavage into shorter oligonucleotide fragments. These metabolic processes occur intracellularly, particularly within hepatocytes following receptor-mediated endocytosis. Unlike small molecule drugs, eplontersen does not rely heavily on cytochrome P450 enzymes, reducing the potential for hepatic enzyme-mediated drug interactions. The ligand conjugation facilitates targeted uptake and assists in efficient intracellular metabolism. Metabolic stability is sufficient to maintain monthly dosing intervals.

Elimination:
Metabolites and intact eplontersen are eliminated predominantly via urinary excretion of the oligonucleotide fragments. Renal clearance plays a critical role in the elimination of smaller metabolized fragments following intracellular cleavage. The elimination half-life supports once-monthly dosing, with accumulation studies indicating steady-state plasma levels within expected therapeutic ranges. Dose adjustments in patients with renal impairment have not been definitively established but should be considered cautiously. Overall, the elimination profile supports a favorable balance between efficacy and tolerability in long-term use.

Dosage Forms

Available Dosage Forms:
Wainua is uniquely provided as a ready-to-use single-dose autoinjector containing 45 mg of eplontersen in 0.8 mL of solution intended for subcutaneous injection. There are no other marketed formulations or alternative administration routes, as this ensures precise dosing, ease of use, and improved patient adherence.

Dosages for Adults and Adolescents:
The recommended and only approved dose of Wainua for adults is 45 mg administered subcutaneously once every month (approximately every 28–31 days). This dosing schedule was established based on Phase 3 clinical trial data demonstrating optimal efficacy and safety in the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN).

Specific Patient Populations:
Eplontersen dosing in pediatric, geriatric, or patients with renal or hepatic impairment has not been extensively studied. The clinical trials primarily enrolled adults; hence, caution is advised when administering Wainua to populations outside this group. No formal dose adjustments are currently recommended; however, monitoring and clinical judgment should guide therapy in special populations. The drug should not be used in pregnant or breastfeeding patients without clear medical justification due to potential risks from altered vitamin A metabolism. Patients are also advised to supplement vitamin A to mitigate deficiency induced by treatment.

Detailed Instructions:
The autoinjector should be removed from refrigeration 30 minutes prior to injection to allow it to reach room temperature. Visual inspection of the solution is necessary to confirm clarity and absence of particulate matter. Injection sites include the abdomen, front of the thighs, or outer area of the upper arms (the latter when administered by a caregiver). Injection should be performed once monthly on the same day to maintain steady pharmacologic effect. Missed doses should be administered as soon as possible with resumption of the monthly schedule thereafter.

Mechanism Of Action

Eplontersen is a ligand-conjugated antisense oligonucleotide (LICA) designed to selectively bind to the messenger RNA (mRNA) transcripts encoding transthyretin (TTR), a plasma protein predominantly synthesized in the liver. Upon binding to TTR mRNA, eplontersen induces degradation of both mutant and wild-type TTR mRNA via ribonuclease H-mediated cleavage. This results in a decrease in the hepatic production of the TTR protein, thereby reducing circulating serum TTR levels.

The reduction in TTR protein synthesis addresses the fundamental pathophysiology of hereditary transthyretin-mediated amyloidosis (hATTR), a disease characterized by deposition of misfolded TTR protein aggregates (amyloid fibrils) in peripheral nerves and various organs. By lowering serum TTR protein, eplontersen slows the formation and deposition of new amyloid fibrils, which contributes to halting disease progression and ameliorating neuropathy symptoms.

The ligand conjugation (typically a GalNAc moiety) facilitates targeted delivery by promoting selective uptake of the antisense oligonucleotide into hepatocytes via asialoglycoprotein receptor-mediated endocytosis. This liver tropism enhances potency and reduces systemic exposure, improving safety and efficacy. This mechanism contrasts with other modalities like TTR stabilizers which prevent amyloid aggregation but do not reduce protein production.

Clinical evidence from the Phase 3 NEURO-TTRansform trial demonstrated that treatment with eplontersen resulted in approximately 81% reduction in serum TTR levels compared to baseline. This biochemical effect was correlated with significant improvements in neuropathy impairment scores and patient quality of life measures, validating the mechanism's therapeutic relevance.

Pharmacological Actions

Selective degradation of transthyretin (TTR) mRNA via antisense oligonucleotide mechanism.
Significant reduction of serum TTR protein levels, both mutant and wild-type.
Inhibition of amyloid fibril formation by decreasing TTR availability.
Hepatocyte-targeted delivery through ligand conjugation improves potency.
Modulation of disease progression in hereditary transthyretin-mediated amyloidosis (hATTR).
Improvement in peripheral nerve function through reduced amyloid deposition.
Reduction of TTR protein deposition in tissues.
Beneficial effects on patient-reported quality of life in neuropathic diseases.
Monthly subcutaneous dosing supports sustained pharmacologic action.
Minimal cytochrome P450 involvement reduces drug-drug interaction potential.
Does not affect synthesis of other key plasma proteins, showing molecular specificity.
Potential secondary benefits in cardiac amyloidosis under clinical evaluation.
Mechanism distinct from TTR stabilizers and RNA interference therapies, providing alternative therapeutic strategy.
Ligand conjugation reduces systemic toxicity and enhances therapeutic index.
Rapid onset of TTR protein reduction following initial doses.

Therapeutic Or Clinical Uses

Treatment of polyneuropathy in adults with hereditary transthyretin-mediated amyloidosis (hATTR-PN).
Slowing progression of neuropathic symptoms associated with ATTR amyloidosis.
Reducing serum concentrations of both mutant and wild-type transthyretin protein.
Improving quality of life in patients suffering from hATTR-PN.
Management of neurological impairments secondary to amyloid deposition.
Potential investigational use in transthyretin amyloid cardiomyopathy (ATTR-CM).
Alternative to RNA interference therapies and TTR stabilizers in hereditary amyloidosis.
Adjunctive therapy to delay disease progression in symptomatic patients.
Clinical indication approved based on robust Phase 3 clinical trial efficacy data.
Used in adult patients who are not candidates for or intolerant to other amyloidosis treatments.
Monthly injectable therapy provides convenience and adherence benefit.
Can be administered at home using autoinjector, facilitating patient self-management.
Recommended for patients identified with pathogenic TTR gene mutations manifesting neuropathy.
Incorporated into multidisciplinary care approaches for hereditary amyloidosis.
Off-label uses under study include cardiac phenotype management and earlier disease stages.

Side Or Adverse Effects

Vomiting reported in approximately 9% of patients during clinical trials.
Proteinuria observed in 8% of treated patients indicating renal involvement.
Injection site reactions including pain, erythema, or swelling affecting 7% of patients.
Blurred vision affecting about 6% of recipients.
Cataracts reported in 6% of patients, necessitating regular ophthalmologic monitoring.
Decreased serum vitamin A levels in 15% of patients, requiring supplementation.
Atrioventricular (AV) heart block occurred in about 2% of patients, a serious adverse event.
Potential for night blindness and dry eyes due to vitamin A deficiency.
Infusion-related reactions including local inflammation or hypersensitivity uncommon but possible.
Possible gastrointestinal disturbances such as nausea or abdominal discomfort.
Headache and fatigue reported in some patients during long-term therapy.
Laboratory abnormalities requiring monitoring include renal function and vitamin A serum levels.
Rare risk of hypersensitivity or anaphylactic reactions upon administration.
No significant hepatotoxicity observed but liver function monitoring recommended.
Not recommended during pregnancy due to risk of vitamin A deficiency-related fetal harm.

Precautions

Monitor vitamin A serum levels regularly and administer vitamin A supplementation as advised.
Inspect injection site and solution prior to administration to avoid particulate exposure.
Use cautiously in patients with pre-existing cardiac conduction abnormalities due to AV heart block risk.
Avoid use in pregnant women unless benefits clearly outweigh risks; vitamin A levels can impact fetal development.
Not recommended during breastfeeding until safety is established.
Patients should be educated on signs of visual changes including night blindness and promptly report symptoms.
Adjust administration schedule carefully if doses are missed to maintain monthly regimen.
Maintain proper storage conditions to preserve drug stability and efficacy.
Use with caution in patients with renal impairment; monitor urinary protein excretion.
Ensure appropriate training for patients and caregivers in autoinjector use.
Regular ophthalmic evaluations are advised during treatment to detect early ocular side effects.
Avoid warming methods other than room temperature for autoinjector preparation to prevent degradation.
Monitor for injection site reactions and manage symptomatically as needed.
Counsel patients on potential gastrointestinal side effects and maintain hydration.
Review concomitant medications carefully to avoid potential interactions, particularly vitamin A containing products.

Warnings

Risk of serious vitamin A deficiency and associated ocular toxicity; supplementation required.
Serious cardiac conduction disorders including atrioventricular (AV) heart block reported.
Do not freeze or expose the medication to temperatures above 30°C (86°F) to prevent loss of efficacy.
Use during pregnancy may cause fetal harm due to vitamin A metabolism alterations.
Potential for injection site reactions necessitating vigilance and prompt management.
Patients must be instructed not to use autoinjector if solution is cloudy, discolored, or contains particulates.
Not demonstrated safe or effective in pediatric populations; use limited to adults.
Prolonged storage outside refrigeration beyond 6 weeks is not advised and may compromise treatment.
Risk of hypersensitivity or allergic reactions, though uncommon, must be considered.
Safety and efficacy in patients with severe renal or hepatic impairment not established.
Concomitant use with high-dose vitamin A or beta-carotene supplements can lead to toxicity.
May cause ocular adverse effects requiring discontinuation or dose modification.
Patients with pre-existing eye disorders should be monitored closely during therapy.
Careful assessment required before initiating therapy in patients with cardiac disorders.
Ensure adherence to dosing schedule to prevent disease progression.

Contraindication

Known hypersensitivity to eplontersen or any of the excipients in Wainua.
Patients with history of severe hypersensitivity reactions to antisense oligonucleotide therapies.
Use in pediatric patients has not been established and is contraindicated pending safety data.
Contraindicated in patients who cannot adhere to vitamin A supplementation due to risk of deficiency.
Patients with untreated severe vitamin A deficiency due to risk of exacerbation.
Should not be used if solution appearance is altered (cloudiness or discoloration).
Use contraindicated if autoinjector has been frozen or stored improperly.
Not recommended during pregnancy unless no suitable alternative and benefits exceed risks.
Contraindicated if active or uncontrolled cardiac conduction disturbances exist without cardiology consultation.
Patients with concurrent participation in another investigational drug study for TTR amyloidosis.
Avoid in patients with severe renal impairment unless under close monitoring.
Contraindicated in cases with known allergic reactions to ligand conjugates used in oligonucleotide therapy.
Presence of severe injection site infections is a relative contraindication until resolved.
Do not use concurrently with experimental gene therapies targeting transthyretin to avoid interaction.
Contraindications extend to patients intolerant to components of autoinjector device or excipients.

Drug Interactions

Vitamin A and beta-carotene supplements: concomitant use requires careful management due to risk of hypervitaminosis A or masking of deficiency.
No significant cytochrome P450 enzyme interactions documented due to antisense oligonucleotide metabolism pathway.
Potential additive effects with other hepatically metabolized drugs should be monitored cautiously.
No evidence of interaction with common cardiac medications but close monitoring advised in patients with AV block risk.
Interactions with other amyloidosis treatments (e.g., tafamidis, patisiran) have not been extensively studied; combination therapy requires clinical judgment.
Concomitant use with nephrotoxic agents may exacerbate renal adverse effects; monitor proteinuria carefully.
Immunomodulatory or immunosuppressive agents may alter adverse event profile but no direct pharmacokinetic interactions anticipated.
No known significant interaction with common anticoagulants or antiplatelet agents.
Theoretical risk of interaction with other oligonucleotide therapies leading to overlapping toxicities.
Herbal supplements with antioxidant properties have no documented interaction but should be reported to healthcare provider.
No interaction with oral contraceptives noted but data limited.
Drug-drug interaction potential is low due to targeted hepatic uptake and intracellular metabolism.
Avoid simultaneous use of medications known to cause ocular toxicity or retinal damage without ophthalmologic supervision.
No known interference with standard laboratory assays reported.
Interactions with monoclonal antibodies or biologics used in neuropathy or cardiomyopathy under investigation.

Preparations Of The Drug

Eplontersen sodium is the active ingredient in Wainua.
Available as a sterile solution at a concentration of 45 mg/0.8 mL in a single-dose prefilled autoinjector.
Inactive ingredients include dibasic sodium phosphate anhydrous, monobasic sodium phosphate dihydrate, sodium chloride, water for injection.
pH is adjusted with hydrochloric acid and/or sodium hydroxide to maintain stability and isotonicity.
The formulation is preservative-free to reduce injection site reactions and hypersensitivity.
The autoinjector device is designed for subcutaneous self-administration with safety features to prevent needle-stick injury.
Supplied in a carton containing one autoinjector per box, intended for monthly dosing.
Packaged for refrigerated storage between 2°C to 8°C (36°F to 46°F) with the option for limited room temperature storage.
Light-sensitive and should be stored in the original carton to protect from light exposure.
No added dyes or latex components to minimize allergenicity.
Manufactured under stringent aseptic conditions to ensure sterility.
The drug preparation must not be frozen and discarded if exposed to freezing temperatures.
Designed for subcutaneous injection in abdominal area, thighs, or upper outer arm by trained patients or caregivers.
Instructed to be warmed to room temperature prior to administration for patient comfort and optimal absorption.
Approved and marketed by AstraZeneca Pharmaceuticals LP in cooperation with Ionis Pharmaceuticals, Inc.